{
    "EVIDENCE": {
        "type": "evidence",
        "assertions": [
            {
                "type": "assertion",
                "description": "Activating mutations in JAK1 (SH2-, pseudokinase -and kinase- domains) have been reported in approximately 5-20% of cases of T-Cell Acute Lymphoblastic Leukemia, in \"Ph-like ALL\" and in less than 5% of Acute Myeloid Leukemia.  Some, but not all, of these mutations have been shown to be inhibitable by ATP-competitive JAK inhibitors or Type I interferon.",
                "gene": {
                    "name": "JAK1"
                },
                "variants": [
                    {
                        "name": "JAK1 any mutation"
                    }
                ],
                "tier": 2,
                "tumor_types": [
                    "T Lymphoblastic Leukemia/Lymphoma",
                    "Acute Myeloid Leukemia",
                    "Acute Leukemia of Unspecified Cell Type",
                    "Anemia, Unspecified",
                    "Atypical Chronic Myeloid Leukemia",
                    "B Lymphoblastic Leukemia/Lymphoma",
                    "Chronic Myeloid Leukemia",
                    "Chronic Myelomonocytic Leukemia",
                    "Chronic Neutrophilic Leukemia",
                    "Cytopenia",
                    "Eosinophilia",
                    "Essential Thrombocythemia",
                    "Histiocytic and Dendritic Cell Neoplasms",
                    "Langerhans Cell Histiocytosis",
                    "Leukocytosis",
                    "Leukopenia",
                    "Mast Cell Neoplasm",
                    "MDS with Ring Sideroblasts",
                    "Monocytosis",
                    "Myelodysplastic Syndrome",
                    "Myelodysplastic/Myeloproliferative Neoplasm",
                    "Myeloproliferative Neoplasm",
                    "Myeloid Neoplasm",
                    "Other Acute Leukemia",
                    "Polycythemia Vera",
                    "Polycythemia",
                    "Primary Myelofibrosis",
                    "Thrombocytopenia, Unspecified",
                    "Thrombocytosis"
                ],
                "tissue_types": [
                    "Blood",
                    "Bone Marrow"
                ]
            }
        ],
        "source": {
            "citations": [
                "Flex E, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205(4):751-8",
                "Aranaz P, et al. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. Cancer Genet Cytogenet 2010;199(1):1-8",
                "Asnafi V, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2010;148(1):178-9",
                "Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63",
                "Wang Q, et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 2011;96(12):1808-14",
                "Hornakova T, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011;96(6):845-53",
                "Hornakova T, et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010;115(16):3287-95",
                "Mullighan CG, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106(23):9414-8",
                "Xiang Z, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111(9):4809-12",
                "National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia (Version 1.2018)."
            ]
        }
    },
    "GENE": {
        "type": "gene",
        "name": "JAK1",
        "variants": [
            {
                "name": "JAK1 any mutation",
                "evidence_count": 1
            }
        ]
    },
    "VARIANTS": [
        {
            "type": "variant",
            "name": "JAK1 any mutation",
            "gene": "JAK1",
            "evidence": {
                "type": "evidence",
                "sources": [
                    "Flex E, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008;205(4):751-8",
                    "Aranaz P, et al. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes. Cancer Genet Cytogenet 2010;199(1):1-8",
                    "Asnafi V, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol 2010;148(1):178-9",
                    "Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63",
                    "Wang Q, et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica 2011;96(12):1808-14",
                    "Hornakova T, et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011;96(6):845-53",
                    "Hornakova T, et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010;115(16):3287-95",
                    "Mullighan CG, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106(23):9414-8",
                    "Xiang Z, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111(9):4809-12",
                    "National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia (Version 1.2018)."
                ]
            },
            "assertions": [
                {
                    "type": "assertion",
                    "description": "Activating mutations in JAK1 (SH2-, pseudokinase -and kinase- domains) have been reported in approximately 5-20% of cases of T-Cell Acute Lymphoblastic Leukemia, in \"Ph-like ALL\" and in less than 5% of Acute Myeloid Leukemia.  Some, but not all, of these mutations have been shown to be inhibitable by ATP-competitive JAK inhibitors or Type I interferon.",
                    "tumor_types": [
                        "T Lymphoblastic Leukemia/Lymphoma",
                        "Acute Myeloid Leukemia",
                        "Acute Leukemia of Unspecified Cell Type",
                        "Anemia, Unspecified",
                        "Atypical Chronic Myeloid Leukemia",
                        "B Lymphoblastic Leukemia/Lymphoma",
                        "Chronic Myeloid Leukemia",
                        "Chronic Myelomonocytic Leukemia",
                        "Chronic Neutrophilic Leukemia",
                        "Cytopenia",
                        "Eosinophilia",
                        "Essential Thrombocythemia",
                        "Histiocytic and Dendritic Cell Neoplasms",
                        "Langerhans Cell Histiocytosis",
                        "Leukocytosis",
                        "Leukopenia",
                        "Mast Cell Neoplasm",
                        "MDS with Ring Sideroblasts",
                        "Monocytosis",
                        "Myelodysplastic Syndrome",
                        "Myelodysplastic/Myeloproliferative Neoplasm",
                        "Myeloproliferative Neoplasm",
                        "Myeloid Neoplasm",
                        "Other Acute Leukemia",
                        "Polycythemia Vera",
                        "Polycythemia",
                        "Primary Myelofibrosis",
                        "Thrombocytopenia, Unspecified",
                        "Thrombocytosis"
                    ],
                    "tissue_types": [
                        "Blood",
                        "Bone Marrow"
                    ],
                    "tier": 2,
                    "gene": "JAK1"
                }
            ]
        }
    ],
    "ASSERTION": {
        "type": "assertion",
        "description": "Activating mutations in JAK1 (SH2-, pseudokinase -and kinase- domains) have been reported in approximately 5-20% of cases of T-Cell Acute Lymphoblastic Leukemia, in \"Ph-like ALL\" and in less than 5% of Acute Myeloid Leukemia.  Some, but not all, of these mutations have been shown to be inhibitable by ATP-competitive JAK inhibitors or Type I interferon.",
        "gene": {
            "name": "JAK1"
        },
        "variants": [
            {
                "name": "JAK1 any mutation"
            }
        ],
        "tier": 2,
        "tumor_types": [
            "T Lymphoblastic Leukemia/Lymphoma",
            "Acute Myeloid Leukemia",
            "Acute Leukemia of Unspecified Cell Type",
            "Anemia, Unspecified",
            "Atypical Chronic Myeloid Leukemia",
            "B Lymphoblastic Leukemia/Lymphoma",
            "Chronic Myeloid Leukemia",
            "Chronic Myelomonocytic Leukemia",
            "Chronic Neutrophilic Leukemia",
            "Cytopenia",
            "Eosinophilia",
            "Essential Thrombocythemia",
            "Histiocytic and Dendritic Cell Neoplasms",
            "Langerhans Cell Histiocytosis",
            "Leukocytosis",
            "Leukopenia",
            "Mast Cell Neoplasm",
            "MDS with Ring Sideroblasts",
            "Monocytosis",
            "Myelodysplastic Syndrome",
            "Myelodysplastic/Myeloproliferative Neoplasm",
            "Myeloproliferative Neoplasm",
            "Myeloid Neoplasm",
            "Other Acute Leukemia",
            "Polycythemia Vera",
            "Polycythemia",
            "Primary Myelofibrosis",
            "Thrombocytopenia, Unspecified",
            "Thrombocytosis"
        ],
        "tissue_types": [
            "Blood",
            "Bone Marrow"
        ]
    }
}